beta
/Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 Second Extraordinary Shareholders Meeting Materials
NEWS

Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 Second Extraordinary Shareholders Meeting Materials

Shanghai Stock Exchange
2026/06/05

Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.’s second extraordinary shareholders’ meeting in 2026

discuss

Capital

material

2026.06.10

Directory

Instructions for the Second Extraordinary Shareholders’ Meeting in 2026 .............3 Agenda for the Second Extraordinary Shareholders’ Meeting in 2026 .............4 Proposal 1: Proposal on the Unfulfilled Restriction Conditions of the Third Unlocking Period of the 2023 Restricted Stock Incentive Plan and the Repurchase and Cancellation of Part of the Restricted Stocks ............. 6 Proposal 2: Proposal on Reducing Registered Capital and Amending the Articles of Association .............12

Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

Instructions for the Second Extraordinary Shareholders Meeting in 2026

In order to safeguard the legitimate rights and interests of all shareholders and ensure the normal order and efficiency of the shareholders' meeting, in accordance with the "Company Law", "Rules for Shareholders' Meetings of Listed Companies", "Shanghai Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 1 - Standardized Operations" and the "Articles of Association" and other relevant regulations, the instructions for this shareholders' meeting are formulated as follows:

  1. The meeting shall be conducted in accordance with laws, regulations, relevant provisions and the Articles of Association, and participants shall consciously maintain the order of the meeting.

  2. Shareholders who participate in shareholders' meetings shall enjoy the right to speak, question, vote and other rights in accordance with the law, and shall conscientiously perform their legal obligations and shall not infringe on the legitimate rights and interests of other shareholders.

  3. Participating shareholders or shareholder representatives should register for the meeting at Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") from 9:00 a.m. to 11:00 p.m. and from 14:00 p.m. to 16:00 p.m. on June 8, 2026, or by email or other means. Shareholders and shareholder representatives who have registered to participate in the meeting must bring their identity certificate, power of attorney and other documents to the office building at No. 8 Yantai 1st Road, Pingfang Development Zone, Harbin before 13:55 pm on June 10, 2026 to sign in and register before attending the meeting.

  4. Shareholders should raise their hands to ask questions and follow the arrangements of the host. Before speaking and asking questions, you should first introduce your shareholder status (or the shareholder unit you represent), number of shares held, etc. Speeches and questions should focus on the agenda of this meeting, and each speaker should not exceed 3 minutes. No more speeches will be scheduled after the voting on the motion begins.

  5. The meeting adopts a combination of on-site voting and online voting for voting. Shareholders participating in online voting must follow the specific operating procedures in the meeting notice to vote during the trading session on June 10, 2026. The on-site meeting adopts a registered voting method. The shareholders or shareholder representatives present at the meeting have one voting right for each share of the company they hold and fill in their voting opinions item by item on the voting ticket. The votes at the meeting will be counted and monitored by shareholder representatives and witness lawyers.

  6. During the shareholders' meeting, participants are asked to turn off their mobile phones or set them to silent mode. Individual recording, photography and video recording are prohibited.

Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

Agenda for the second extraordinary shareholders’ meeting in 2026

1. Meeting time:

On-site meeting time: 14:00 on June 10, 2026

Online voting system and voting time:

Online voting system: Shanghai Stock Exchange Shareholders Meeting online voting system

Online voting starts and ends on June 10, 2026

Until June 10, 2026

Using the Shanghai Stock Exchange's online voting system, the voting time through the trading system voting platform is the trading time period on the day the shareholders' meeting is held, that is, 9:15-9:25, 9:30-11:30, 13:00-15:00; the voting time through the Internet voting platform is 9:15-15:00 on the day the shareholders' meeting is held.

  1. Meeting location: Conference Room, Office Building, No. 8, Yantai 1st Road, Pingfang Development Zone, Harbin

3. Meeting host: Chairman Fang Fuxin

4. Meeting agenda:

(1) Announce the start of the meeting and introduce the participating shareholders (holding more than 5% of the shares) and attendees

(2) Whether the number of shareholders announced to participate in the on-site shareholders’ meeting, the number of shares held, and the proportion of the total share capital comply with the relevant provisions of the Company Law and the Articles of Association

(3) Read out the instructions for the shareholders’ meeting and elect vote counters and scrutineers

(4) Review of shareholders’ meeting resolutions:

Serial number Bill name

Regarding the lifting of restrictions on sales during the third lifting period of the 2023 Restricted Stock Incentive Plan

Unfulfilled proposal to repurchase and cancel some restricted stocks

2 Proposal on reducing registered capital and amending the "Articles of Association"

(5) Shareholders’ speeches, questions and the company’s answers to questions

(6) Shareholders vote on proposals

(7) The host announces that the staff will count the votes and the meeting will be adjourned.

(8) The scrutineers read out the voting results

(9) Lawyers read out legal opinions

(10) Directors and board secretaries present at the meeting sign on the shareholders’ meeting resolutions, meeting minutes and other documents

(11) The host announces the end of the meeting

Proposal 1: Regarding the third lifting of sales restrictions under the 2023 Restricted Stock Incentive Plan

The conditions for lifting the sales restrictions during the period have not been met and the proposal to repurchase and cancel some restricted stocks

Dear shareholders and shareholder representatives:

In view of the fact that the performance of the company's 2023 restricted stock incentive plan (hereinafter referred to as the "Incentive Plan") in 2025 did not meet the assessment standards for the third unlocking period of this incentive plan, the conditions for unlocking the third unlocking period of this incentive plan were not met, and at the same time, 4 incentive targets in the company's incentive plan have resigned due to personal reasons. In accordance with the relevant provisions of the 2018 Restricted Stock Incentive Plan (Draft) (hereinafter referred to as the "Incentive Plan"), the company will repurchase and cancel the 831,995 restricted shares that have been granted but have not yet been released from sale restrictions. The relevant information is now announced as follows:

1. Decision-making procedures and information disclosure status of this incentive plan

(1) On June 7, 2023, the company held the second meeting of the fifth session of the Board of Directors, which reviewed and approved the "Proposal on the "2023 Restricted Stock Incentive Plan (Draft) of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd." and its summary, the "Proposal on the Implementation Assessment and Management Measures for the 2023 Restricted Stock Incentive Plan of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd." and "Requesting the General Meeting of Shareholders to Authorize the Board of Directors to Handle the 2023 Restricted Stock Incentive Plan" Proposal on Matters Related to the 2016 Restricted Stock Incentive Plan" and other proposals. The associated directors have abstained from voting when reviewing relevant matters, and the company's independent directors have expressed independent opinions on the proposals related to this incentive plan.

On the same day, the company held the second meeting of the fifth session of the Board of Supervisors, and reviewed and approved the "Proposal on the <Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2023 Restricted Stock Incentive Plan (Draft)> and its Summary", the "Proposal on the <Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2023 Restricted Stock Incentive Plan Implementation Assessment and Management Measures>" and the "Proposal on the Verification of <Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2023 Restricted Stock Incentive Plan" Proposal on the List of Incentive Objects of the Annual Restricted Stock Incentive Plan>. The company's board of supervisors verified the relevant matters of this incentive plan and issued relevant verification opinions.

(2) From June 8, 2023 to June 18, 2023, the company publicized the names and positions of the incentive recipients planned to be awarded under this incentive plan within the company. During the public announcement period, the company's supervisory board did not receive any objections related to the incentive objects. For details, please refer to the "Explanation and Verification Opinions of the Board of Supervisors of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. on the Disclosure and Verification Opinions of the List of Incentive Objects of the 2023 Restricted Stock Incentive Plan" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) (Announcement No.: Lin 2023-052). On June 20, 2023, the company disclosed the "Self-examination Report of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. on the Purchase and Sale of Company Stocks by Insiders of the 2023 Restricted Stock Incentive Plan" (Announcement Number: Lin 2023-053).

(3) On June 26, 2023, the company held the first extraordinary general meeting of shareholders in 2023 to review and adopt the "Proposal on the <Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2023 Restricted Stock Incentive Plan (Draft)> and its Summary", the "Proposal on the <Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. Proposal on Matters Related to the 2016 Restricted Stock Incentive Plan" and other proposals. This incentive plan was approved by the first extraordinary general meeting of shareholders in 2023. The board of directors is authorized to determine the grant date of this incentive plan, grant restricted stocks to incentive objects when the incentive objects meet the conditions, and handle all matters necessary for the grant of restricted stocks.

(4) On July 3, 2023, the company held the third meeting of the fifth board of directors and the third meeting of the fifth board of supervisors, and reviewed and approved the "Proposal on Adjusting Matters Related to the 2023 Restricted Stock Incentive Plan" and the "Proposal on Granting Restricted Stocks to Incentive Objects". Related directors have abstained from voting when reviewing relevant matters, and the company's independent directors have expressed independent opinions on relevant proposals. The company's board of supervisors verified the list of incentive targets for the grant of restricted stocks and other related matters and issued verification opinions.

(5) On April 3, 2024, the company held the eighth meeting of the fifth board of directors and the seventh meeting of the fifth board of supervisors. On May 20, 2024, the company held the 2023 annual shareholders' meeting, which reviewed and approved the "Proposal of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. on the company's repurchase and cancellation of restricted stocks that have been granted to some incentive targets but have not yet been released from sale restrictions."

(6) On June 14, 2024, the company held the 11th meeting of the fifth board of directors and the ninth meeting of the fifth board of supervisors. On August 23, 2024, the company held the second extraordinary shareholders' meeting of 2024, which reviewed and approved the "Proposal of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. on the repurchase and cancellation of some restricted stocks in the 2023 restricted stock incentive plan."

(7) On March 25, 2025, the company held the 19th meeting of the fifth board of directors and the 16th meeting of the fifth board of supervisors, and reviewed and approved the "Proposal on the Company's Repurchase and Cancellation of Restricted Stocks that have been granted but have not yet been released from sale restrictions to some of the resignation incentive objects".

(8) On April 29, 2025, the company held the 21st meeting of the fifth board of directors and the 17th meeting of the fifth board of supervisors, and reviewed and approved the "Proposal on the Repurchase and Cancellation of Part of the Restricted Stocks in the 2023 Restricted Stock Incentive Plan".

(9) On May 25, 2026, the company held the first meeting of the sixth session of the Board of Directors, which reviewed and approved the "Proposal on the Unfulfilled Restriction Conditions during the Third Unlocking Period of the 2023 Restricted Stock Incentive Plan and the Repurchase and Cancellation of Part of the Restricted Stocks."

2. Relevant information on the repurchase and cancellation of restricted stocks

(1) Reasons for cancellation of this repurchase

  1. The conditions for lifting the sales restrictions during the third lifting period have not been met.

According to the relevant provisions of the "Incentive Plan": If the company fails to meet the performance assessment targets, all restricted stocks planned to be lifted by the incentive targets in the current period will not be lifted from the sales restrictions, and the unrestricted portion will be repurchased and canceled by the company.

The corresponding performance assessment target of this incentive plan in 2025 is to achieve a net profit attributable to shareholders of listed companies of RMB 1.098 billion in 2025. The company's actual net profit attributable to shareholders of listed companies in 2025 is -13.67 100 million yuan, has not reached the assessment standards for the third unlocking period of this incentive plan, and the conditions for unlocking the third unlocking period of this incentive plan have not been met. According to the relevant provisions of the "Administrative Measures" and the company's "Incentive Plan", the company plans to repurchase and cancel 637,003 restricted shares held by 18 incentive recipients that have been granted but have not yet been released.

  1. The incentive target resigns

According to the relevant provisions of the "Incentive Plan": If the incentive target voluntarily resigns, is terminated from the labor relationship due to personal reasons, or the contract is not renewed when the contract expires, if the restricted stock granted to him has reached the conditions for lifting the sales restrictions in the current year, this part can still be enjoyed by the incentive target. The restricted stock that has been granted to the incentive target but has not been released from the sales restriction cannot be lifted, and the company will repurchase and cancel it according to the grant price.

Four of the incentive targets in this incentive plan have resigned due to personal reasons. In accordance with the relevant provisions of the "Management Measures" and the "Incentive Plan", the company will repurchase and cancel the restricted stocks granted to them at the grant price.

(2) The number of restricted shares canceled during this repurchase and the repurchase price

  1. Repurchase quantity

The number of restricted shares canceled during this repurchase was 831,995 shares.

  1. Buy-back price

The company disclosed the "Announcement on the 2023 Annual Profit Distribution Plan of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd." on April 30, 2024. The 2023 Annual Shareholders Meeting reviewed and approved the distribution plan - a cash dividend of RMB 2.00 (tax included) for every 10 shares.

The company disclosed the "Announcement on the 2024 Annual Profit Distribution Plan of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd." on April 30, 2025. The 2024 Annual Shareholders Meeting reviewed and approved the distribution plan - a cash dividend of RMB 1.50 (tax included) for every 10 shares.

According to the provisions of the "Incentive Plan": "After the restricted stocks granted to the incentive objects have been registered, if the company has converted capital reserves into equity, distributed stock dividends, split shares, allotments or reductions, dividends and other matters that affect the company's total share capital or the company's stock price, the company should make corresponding adjustments to the repurchase quantity and repurchase price of the restricted shares that have not yet been released." Since the company will pay dividends before the repurchase, the repurchase price needs to be adjusted during the repurchase. The adjustment method is as follows:

P=P-V

Among them: P is the adjusted repurchase price per restricted stock, P is the pre-adjusted repurchase price per restricted stock (8.432 yuan/share); V (the sum of dividends per share in 2023 and 2024) is the dividend amount per share (0.35 yuan/share).

The repurchase price for the resigning incentive objects to repurchase and cancel restricted stocks is the adjusted repurchase price of 8.082 yuan/share.

If the conditions for repurchasing and canceling restricted stocks are not fulfilled during the third unlocking period of this incentive plan, the repurchase price will be the adjusted repurchase price, plus the deposit interest calculated based on the three-year deposit benchmark interest rate of the People's Bank of China, and the final repurchase price is 8.385 yuan/share.

(3) Funds and sources of this repurchase and cancellation

Calculated based on the above repurchase quantity and repurchase price, the total amount of repurchase funds is 6,917,195.55 yuan, and the source of funds is the company's own funds.

3. Changes in the company’s share capital structure after the completion of this repurchase and cancellation

After the completion of this restricted stock repurchase and cancellation, the company's total share capital will change from 940,859,283 shares to 939,403,292 shares. The company will promptly disclose changes in the company's total number of shares and capital structure after the completion of the restricted stock repurchase and cancellation.

Before this change Amount of this change Nature of shares after this change

Number of shares as a share of total share capital Number of shares Number of shares as a share of total share capital

(share) ratio (share) (share) ratio

Circulating shares with selling restrictions 1,455,991 0.15% -1,455,991 0 - Circulating shares with no selling conditions 939,403,292 99.85% 0 939,403,292 100.00% Total 940,859,283 100.00% -1,455,991 939,403,292 100.00%

Note: The company held the 21st meeting of the fifth board of directors and the 17th meeting of the fifth board of supervisors on April 29, 2025, and reviewed and approved the "Proposal on the Repurchase and Cancellation of Part of the Restricted Stocks in the 2023 Restricted Stock Incentive Plan". At the same time, It is intended to repurchase and cancel the 623,996 restricted shares held by 22 incentive recipients that have been granted but have not been released from sale restrictions. The cancellation process has not yet been completed. The change value in the above table includes the number of restricted shares that have not yet been cancelled. The actual changes in the share capital structure shall be subject to the share structure table issued by the Shanghai Branch of China Securities Depository and Clearing Co., Ltd. after the repurchase and cancellation is completed.

After the repurchase and cancellation is completed, the company's controlling shareholders and actual controllers will not change, and the company's equity distribution still meets the conditions for listing.

4. The impact of this repurchase and cancellation of some restricted stocks on the company

This repurchase and cancellation of restricted stocks that have been granted to retired employees and some incentive targets but have not yet been released will not have a significant impact on the company's operating results and financial status, nor will it affect the diligence of the company's management team. The company's management team will continue to perform its work responsibilities seriously and be committed to creating value for shareholders. The company will perform corresponding capital reduction procedures in accordance with the law after the completion of this repurchase.

The above proposals are invited to be reviewed by shareholders and shareholder representatives.

Board of Directors of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. June 10, 2026

Proposal 2: Proposal on reducing registered capital and amending the Articles of Association

Dear shareholders and shareholder representatives:

1. Situations related to reduction of registered capital

The company held the 30th meeting of the fifth board of directors and the first extraordinary shareholders' meeting in 2026 on March 10, 2026 and April 20, 2026, respectively, and reviewed and approved the "Proposal on Cancellation of Treasury Stocks in the Company's Special Securities Account for Repurchase", and planned to cancel 137,232 shares deposited in the special securities account for repurchase. For details, please refer to the "Announcement of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. on the cancellation of the company's repurchase of treasury shares in the special securities account" (announcement number: Lin 2026-016) and "Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on March 11, 2026 and April 21, 2026 respectively. Announcement of Resolutions of the First Extraordinary Shareholders Meeting of 2020 (Announcement No.: Pro 2026-034).

On May 25, 2026, the company held the first meeting of the sixth session of the Board of Directors, which reviewed and approved the "Proposal on the Unfulfilled Restriction Conditions of the Third Lifting Period of the 2023 Restricted Stock Incentive Plan and the Repurchase and Cancellation of Part of the Restricted Stocks". According to the relevant provisions of the "Equity Incentive Management Measures for Listed Companies" and the company's "Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2023 Restricted Stock Incentive Plan (Draft)", in view of the company's 2023 The performance of the restricted stock incentive plan (hereinafter referred to as the "Incentive Plan") in 2025 does not meet the assessment standards for the third unlocking period of this incentive plan. The conditions for unlocking the third unlocking period of this incentive plan have not been met. At the same time, 4 incentive objects in this incentive plan have resigned due to personal reasons. The company will use the above 831,995 that have been awarded but have not yet been lifted. For details, please refer to the "Announcement of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. on the Unfulfilled Restriction Conditions of the Third Unlocking Period of the 2023 Restricted Stock Incentive Plan and the Repurchase and Cancellation of Part of the Restricted Stocks" disclosed by the company (Announcement Number: Lin 2026-052).

After the above-mentioned repurchase and cancellation is completed, the company's registered capital will be changed from 940,372,519 yuan to 939,403,292 yuan, and the company's total share capital will be changed from 940,372,519 shares to 939,403,292 shares.

2. The specific revisions to the "Articles of Association" are as follows:

Serial number Before revision After revision

Article 6 The registered capital of the company is RMB. Article 6 The registered capital of the company is RMB 940,372,519. 939,403,292 yuan.

Article 21 The total number of shares of the company is Article 21 The total number of shares of the company is

940,372,519 shares, all ordinary shares. 939,403,292 shares, all ordinary shares.

Article 119 The Board of Directors shall determine external investment, acquisition and sale of assets, asset mortgage, external guarantee investment, acquisition and sale of assets, asset mortgage, external guarantee matters, entrusted financial management, related transactions, external donations and guarantee matters, entrusted financial management, related transactions, external donations, etc., and establish strict review and decision-making procedures; for major investment projects, relevant experts and professionals shall be organized Large investment projects should be reviewed by relevant experts and professionals and submitted to the shareholders' meeting for approval. Conduct review and submit to shareholders meeting for approval.

Without violating laws, regulations and other provisions of these Articles of Association, the company's purchase or sale of assets, external investment (including entrusted financial management, entrusted loans, external investment in subsidiaries (including entrusted financial management, entrusted loans, investment in subsidiaries, etc.)), provision of financial assistance (including interest or company investment, etc.), leasing or leasing assets, signing management of interest-free loans, entrusted loans, etc.), provision of guarantees (including contracts (including entrusted operations, entrusted operations, etc.), guarantees for holding subsidiaries, etc.), leasing or leasing assets, donating or receiving assets (except for donated cash assets), signing management contracts (including entrusted operations, entrusted creditor's rights or debt reorganization, transfer operations of research and development projects, etc.), donating or receiving assets (receiving cash or transfer, signing a license agreement, giving up rights (including releasing assets), creditor's rights or debt restructuring, research and development) The transfer or transfer of projects, signing of license agreements, and renunciation of transaction matters shall comply with the following provisions: Rights (including waiver of preemptive rights, priority subscription of capital contributions, etc.)

The review and decision-making of transaction matters such as rights, etc.) shall be observed. When the company provides guarantees and financial assistance, there are no following provisions: Regardless of the amount incurred, it must be submitted to the board of directors for review... In addition to approval, when the company provides guarantees and financial assistance, it must be reviewed and approved by more than half of all directors of the board of directors. In addition to being public, it shall also be reviewed and approved by two-thirds of the directors present at the board meeting and shall be disclosed in a timely manner. When the company issues insurance and provides financial assistance as stipulated in Article 47 and provides guarantee assistance as stipulated in Article 46 of the Articles of Association, it shall also propose the matter and provide financial assistance as stipulated in Article 47 to the shareholders' meeting for review and approval after the board of directors has reviewed and approved it.

When making an item, the stock certificate shall also be submitted after deliberation and approval by the board of directors...

It was reviewed and approved by the Eastern Conference.

…

Article 121 The Chairman shall exercise the following powers: Article 121 The Chairman shall exercise the following powers:

(1) Preside over the shareholders’ meeting, convene and preside over the board of directors’ meeting; (1) Preside over the shareholders’ meeting, convene and preside over the board of directors’ meeting;

(2) Supervise and inspect the implementation of board resolutions; (2) Supervise and inspect the implementation of board resolutions;

(3) Business plans and investments decided by the company’s board of directors (3) Adjustment decision-making power within 5% of the amount involved in the business plan, investment plan, and annual financial budget plan decided by the company’s board of directors; (4) Adjustment decision-making power within 5% of the amount involved in the plan;

(4) Purchase, sale, disposal, leasing, leasing and other matters other than the business plan and investment plan decided by the company's board of directors, including the purchase, sale, disposal, leasing plan, annual financial budget plan and other matters (excluding external investment) involved in the purchase, sale, disposal, leasing, leasing out and other matters (except the amount does not reach the decision-making power for review and approval of the board of directors; including external investment), the amount involved does not reach the decision-making power of the board of directors for review and approval;

(5) Sign stocks, bonds and other documents issued by the company; (6) Sign board of directors documents, and other documents that should be signed by public securities; legal representatives;

(6) Signing of board of directors documents and other documents that should be signed by the company’s legal representative in the event of force majeure such as natural disasters;

(7) In the event of force majeure such as a major natural disaster, the company shall have special rights to deal with the company's interests, and shall report to the company's board of directors and shareholders' meeting after the incident on the company's affairs in compliance with laws and regulations in case of emergency;

(8) Other powers granted to the board of directors after the event.

Company board of directors and shareholder meeting reports;

(8) Other powers granted by the board of directors.

Except for the above amendments, the remaining contents of the Articles of Association remain unchanged.

According to the "Company Law of the People's Republic of China" and the "Articles of Association", the above-mentioned reduction of registered capital and amendment of the "Articles of Association" have been reviewed and approved at the first meeting of the company's sixth board of directors, and the shareholders' meeting has been submitted to authorize the board of directors, and the board of directors has authorized the company's operating management to handle relevant procedures such as articles of association filing, industrial and commercial change registration and other related matters. The above changes are ultimately subject to approval by the industrial and commercial registration authority.

The full text of the revised Articles of Association can be found on the website of the Shanghai Stock Exchange (www.sse.com.cn).

The above proposals are invited to be reviewed by shareholders and shareholder representatives.

Board of Directors of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

June 10, 2026